| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of Obstetrics/Gynecology (R.A., S.S., K.H.M.), Pathology (C.K.), and Pediatrics (M.O.C.), Washington University School of Medicine, St. Louis, Missouri 63110; and Department of Physiology (A.M., C.I.C.), University of Alberta, Edmonton, Alberta, Canada T6G 2H7
Address all correspondence and requests for reprints to: Dr. Kelle Moley, Washington University School of Medicine, Department of Obstetrics/Gynelcology, Box 8064, St. Louis, Missouri 63110. E-mail: moleyk{at}msnotes.wustl.edu.
 |
ABSTRACT |
|---|
 TOP ABSTRACT INTRODUCTIONRESULTSDISCUSSIONMATERIALS AND METHODSREFERENCES |
|---|
209–316)). This study describes the cloning and characterization of another splice variant, mGLUT9b. Cloned from adult liver, mGLUT9b is identical to mGLUT9a except at the amino terminus. Based on analysis of the genomic structure, the different amino termini result from alternative transcriptional/translational start sites. Expression and localization of these two mGLUT9 splice variants were examined in control and diabetic adult mouse tissues and in cell lines. RT-PCR analysis demonstrated expression of mGLUT9a in several tissues whereas mGLUT9b was observed primarily in liver and kidney. Using a mGLUT9-specific antibody, Western blot analysis of total membrane fractions from liver and kidney detected a single, wide band, migrating at approximately 55 kDa. This band shifted to a lower molecular mass when deglycosylated with peptide-N-glycosidase F. Both forms were present in liver and kidney. Immunohistochemical localization demonstrated basolateral distribution of mGLUT9 in liver hepatocytes and the expression of mGLUT9 in specific tubules in the outer cortex of the kidney. To investigate the alternative amino termini, mGLUT9a and mGLUT9b were overexpressed in kidney epithelium cell lines. Subcellular fractions localized both forms to the plasma membrane. Immunofluorescent staining of polarized Madin Darby canine kidney cells overexpressing mGLUT9 depicted a basolateral distribution for both splice variants. Finally, mGLUT9 protein expression was significantly increased in the kidney and liver from streptozotocin-induced diabetic mice compared with nondiabetic animals. |
INTRODUCTION |
|---|
|
TOPABSTRACTINTRODUCTIONRESULTSDISCUSSIONMATERIALS AND METHODSREFERENCES |
|---|
GLUT9 was recently cloned from human kidney cDNA (6), and our laboratory identified and cloned mouse GLUT9 from a d-7 embryo cDNA library (7). mGLUT9 shares 85% homology with human (h) GLUT9. Sequence analysis has shown that GLUT9 is most similar to GLUT11, and both are categorized into the class II (subgroup) that also includes GLUT5 and GLUT7. mGLUT9a and hGLUT9 exhibit glucose transport activity as demonstrated by 2-deoxyglucose uptake in Xenopus oocytes (7, 8).
A unique feature of mGLUT9 is the existence of multiple splice variants: a long form having 12 transmembrane segments (mGLUT9a; GenBank accession no. AF469480); and two short forms each having a (107-amino acid) deletion resulting in the loss of two transmembrane-spanning domains [mGLUT9a(209–316), GenBank accession no. AF490463; and mGLUT9b(NH2 209–316), GenBank accession no. BC006076 (7)]. A recently cloned long form, mGLUT9b (GenBank accession no. AY776155), is presented here. mGLUT9b is identical to mGLUT9a except that it utilizes an alternative transcriptional/translational start site resulting in a different amino terminus. hGLUT9, hGLUT11, and hGLUT14 have also been reported to have different splice variants, which are differentially expressed in various tissues (8, 9, 10).
Initial characterization of mGLUT9 showed that this transporter is expressed predominantly in adult liver and kidney, tissues critical for maintaining whole-body glucose homeostasis (7). Defining the GLUT expression pattern in these tissues and how this pattern may be altered by diabetes mellitus could help to elucidate the diabetic pathophysiology of these organs. Previous studies have shown that diabetes affects the expression level of GLUTs in a variety of tissues. For example, GLUT2, expressed in the proximal tubules of the kidney, shows an increase in expression under diabetic conditions (11, 12, 13), whereas GLUT1 expression has been shown to decrease (14, 15). Additionally, GLUT1, GLUT2, and GLUT3 have all been shown to be down-regulated in the diabetic mouse embryo (16). Finally, GLUT8, a class III transporter expressed predominantly in embryonic tissue and testis, has shown altered expression patterns in different diabetes models (17). These observations suggest that the GLUTs may play a role in the pathology of the diabetogenic processes associated with these organs and chronic tissue damage.
This study evaluates the localization of the different splice variants, mGLUT9a, and mGLUT9b, in overexpression systems as well as endogenous tissue. In addition, this paper investigates the expression of GLUT9 in adult mouse kidney and liver from control and diabetic animals.
|
RESULTS |
|---|
|
TOPABSTRACTINTRODUCTIONRESULTSDISCUSSIONMATERIALS AND METHODSREFERENCES |
|---|
). mGLUT9b consists of 523 amino acids and is identical to the previously cloned GLUT9 isoform, mGLUT9a, except for the presence of a shorter amino terminus (19 amino acids vs. 34 amino acids). An amino acid sequence alignment of mGLUT9b with the other mouse and human GLUT9 isoforms was performed using the Megalign DNASTAR program (Fig. 2).
|
|
), whereas mGLUT9b was found expressed predominantly in liver and kidney with a lower level of expression detected in heart (Fig. 3B). PCR products obtained with mouse GAPDH -specific primers confirmed the integrity of the cDNA and ensured that equal amounts of cDNA were amplified for each tissue (Fig. 3C).
|
).
|
). The mGLUT9 band corresponded with a positive control sample obtained from Madin Darby canine kidney (MDCK) cells overexpressing mGLUT9. After digestion and deglycosylation with peptide-N-glycosidase F (PNGase F), this band shifted to a lower molecular mass of about 49 kDa (Fig. 5B), consistent with the predicted molecular mass for mGLUT9. To resolve the mGLUT9 splice variants, which differ in size by only 4 kDa, deglycosylated tissue extracts from liver and kidney were separated using a standard (20 x 20 cm) SDS-PAGE gel apparatus. Using this technique, two distinct bands were identified migrating at approximately 49 and 45 kDa. These bands corresponded with bands present in positive control PM fractions generated by overexpressing mGLUT9a and mGLUT9b in MDCK cells. (Fig. 5C). These results confirm that both splice forms of mGLUT9 are expressed in liver and kidney.
|
), thus confirming that this site does serve as an N-glycosylation motif in mGLUT9.
Immunohistochemistry and Immunofluorescence Staining
Immunostaining of paraffin-embedded liver sections demonstrated localization of mGLUT9 in hepatocytes predominantly along the basolateral or sinusoidal membrane surface (Fig. 6, A and B). GLUT2 has previously been localized to the sinusoidal membrane (18). Therefore, to further characterize the location of mGLUT9 in the liver, consecutive sections were stained with both GLUT2 and GLUT9. Dual fluorescence staining confirmed the colocalization of these transporters, demonstrating the basolateral distribution of both GLUT2 and mGLUT9 (Fig. 6, C–E).
|
, A and B). Unlike the findings in the liver tissue, however, 3,3'-diaminobenzidine (DAB) staining of consecutive sections with GLUT2 and GLUT9 showed that GLUT9 existed in a distinct location from GLUT2, which is known to be expressed in the proximal tubules (Fig. 7C). Dual immunofluorescent staining confirmed this distinct localization of GLUT9 from GLUT2 (Fig. 7, D–F).
|
, A–D). No colocalization was seen with any of these markers and mGLUT9.
|
). Western blot analysis of subcellular fractions of these MDCK cells confirmed mGLUT9a and mGLUT9b expression in PM fractions only (Fig. 9B). These results are in contrast to what we found in the human, in which the two splice variants targeted to different surfaces in polarized MDCK cells, one to the basolateral surface and one to the apical surface. The purity of the membrane preparations was confirmed by immunoblotting with an antibody to the 
-subunit of Na/K-ATPase to identify the PM fraction. Na/K-ATPase protein was only seen in PM fractions. The membranes were also immunoblotted with GM130, a Golgi matrix protein and Calnexin, and integral endoplasmic reticulum membrane protein. Neither of these proteins were detected in the PM fraction (data not shown).
|
, A–D). mGLUT9 expression in the liver TM fraction was nearly 2-fold greater in diabetic samples compared with controls (117± 29 vs. 231± 32 relative OD units; P < 0.04) (% normalized to actin control ± SEM), Similarly, mGLUT9 expression in the kidney TM fraction was 1.3-fold increased in diabetic samples (331 ± 12 vs. 440 ± 33 relative OD units; P < 0.05). Immunostaining of paraffin-imbedded tissues showed that the localization of GLUT9 was not altered under diabetic conditions (data not shown).
|
, mGLUT9 b was significantly increased in expression in both kidney and liver from diabetic mice as compared with control mice (P = 0.003, kidney; P = 0.008, liver). With mGLUT9a, there is a tendency for increased expression with diabetes, but this difference did not achieve statistical significance. Skeletal muscle samples were examined from diabetic and nondiabetic mice for control levels of expression of mGLUT9a and b forms by real-time PCR.
|
|
DISCUSSION |
|---|
|
TOPABSTRACTINTRODUCTIONRESULTSDISCUSSIONMATERIALS AND METHODSREFERENCES |
|---|
). This finding suggests the possibility of transcriptional regulation by different promoter elements for each of the splice forms. mGLUT9 is the first of the mGLUTs shown to have multiple splice forms. Among hGLUTs, hGLUT9, hGLUT11, and hGLUT14 (a duplicon of GLUT3) have all been found to have alternative splice forms. A similar pattern of exon organization was described for these transcripts leading to multiple splice variants (8, 9, 10). RT-PCR analysis of mRNA expression reveals that mGLUT9a is present in most tissues, whereas mGLUT9b is predominately expressed in liver and kidney. These data are consistent with Northern blot analysis shown previously for mGLUT9, which suggested the presence of two transcripts in liver and kidney (7). Similar findings were also observed with hGLUT9 splice forms demonstrating selective distribution in different tissues and multiple transcripts on Northern blot (6, 8). This differential expression suggests that these alternative forms may serve selective functions in these particular tissues to maintain glucose homeostasis. Deglycosylation of the PM fractions from kidney and liver revealed the presence of two bands, confirming the protein expression of both transcripts in these tissues. Both of these tissues play a key role in glucose homeostasis by transepithelial transport: the liver by regulating blood glucose levels via glucose storage vs. glucose synthesis and the kidney by reabsorption of glucose from the urine and by gluconeogenesis.
Immunohistochemical staining of liver tissue sections localizes mGLUT9 in polarized, epithelial hepatocytes predominantly along the sinusoidal membrane. Hepatocytes are exposed to blood vessels at this sinusoidal side, which is considered the basolateral surface. The alternative or apical side of the polarized hepatocytes faces the bile canalicular membrane domain (19). GLUT2 is also expressed in hepatocytes and is similarly localized to the basolateral surface (1, 19). We confirm the basolateral expression of mGLUT9 here, by demonstrating the colocalization of both GLUT proteins in the liver. The question remains as to why three GLUTs, GLUT2 and the two forms of GLUT9, would be expressed at the same cell surface. GLUT2 is a low-affinity, high-capacity transporter, which is sensitive only to high concentrations of cytochalasin B. GLUT9 may serve as an alternative bidirectional transporter when the intracellular concentration of glucose in the hepatocytes drops below the Km of GLUT2. For example, experiments have shown that hepatocytes from GLUT2-null mice transport glucose into the blood and this transport is not inhibitable by cytochalasin B (20, 21). Information reported so far on mGLUT9 transport properties (7) and the present observations on localization suggest the possibility that GLUT9 is responsible for transport activity in GLUT2-null hepatocytes. Further studies, however, are needed to address this possible explanation.
Localization of mGLUT9 in the kidney is restricted to specific tubules in the outer cortex of the kidney. Extensive studies have shown that GLUT2 is expressed in proximal convoluted tubules of the kidney and colocalizes with L. tetragonolobus, whereas GLUT1 is expressed in the proximal straight tubules (18). Unlike the findings in hepatocytes, the immunohistochemical staining in kidney indicates that mGLUT9 expression in tubules is entirely distinct from GLUT2 expressing tubules. Several markers were used in this study for colocalization with mGLUT9 to identify the location of this transporter. L. tetragonolobus lectin was used to stain proximal tubules. Tamm-Horsfall antibody was used to label the thick ascending limb of Henle’s loop, and D. biflorus lectin was used to stain collecting ducts. No colocalization was seen with any of these markers, suggesting that mGLUT9 localizes to the basolateral surface of the distal convoluted tubules or connecting tubules of the kidney cortex. No other GLUTs have been identified in this region of the adult nephron; however, one recent report places GLUT12 in the distal tubules and collecting ducts of embryonic d 19 mouse fetuses (22). GLUT8 has also recently been localized to podocytes in murine glomeruli (23). It is possible that mGLUT9 serves to supply the distal tubule with glucose from the interstitium as an energy source critical for ion transport. The presence of another facilitative GLUT on the basolateral surface of the distal tubule is therefore teleologically reasonable to meet the demands of this region of the nephron.
Protein expression of mGLUT9 was, on average, 2-fold higher in membrane fractions from diabetic mouse kidney and liver vs. that from control animal tissue. mRNA expression also was increased in diabetic tissues as compared with controls. Similarly, GLUT2 protein expression has been shown to increase in both tissues in response to induction of hyperglycemia, whereas GLUT1 protein expression decreases (1, 15, 24). By real-time PCR, mGLUT9b is up-regulated to a greater extent in diabetic kidney and liver compared with control and compared with skeletal muscle, which expressed very low levels of both GLUT9 isoforms and did not increase with diabetes. It is not clear why the b form would be preferentially up-regulated. Both isoforms transport glucose, which had been shown previously by us for GLUT9a and now, in this study, for GLUT9b. A recent study with GLUT11, another GLUT with splice variants, reported that all three isoforms, which differ only in their N-terminal sequences, transport glucose with similar affinity (25). Thus it is unlikely that these two isoforms would have different transport characteristics. It is possible that, although the overexpression data did not show a difference, the two isoforms localize to different regions of the cell or organ in vivo, and up-regulation occurs more with GLUT9b for a physiological reason. Further studies are necessary to test this hypothesis as well as understand the factors regulating the mGLUT9a and mGLUT9b expression.
Pericentral regions of the liver and the tubules of the kidney are vulnerable to hypoxia during periods of increased glucose uptake due to increased glucose consumption (26). Therefore, not only blood glucose, but also oxygen content, insulin/glucagon ratio, and ATP/AMP ratio are altered in these two tissues in diabetic animals. Changes in GLUT9 expression may be due to adaptive responses to variations in metabolic and environmental conditions. Analysis of the mGLUT9 promoter regions will elucidate possible regulatory mechanisms likely to be modulated in diabetes. In conclusion, this suggests then that the increase in GLUT9 expression in our diabetic animal model may be due to differential regulation of the splice variants of mGLUT9 in response to hyperglycemia or other physiological conditions known to be altered by diabetic conditions. The pathophysiology of liver and kidney changes, in diabetic mice or humans, may be a result of this adaptive response, and thus further investigation of the mechanisms responsible for this increase in mGLUT9 expression in diabetes is warranted.
|
MATERIALS AND METHODS |
|---|
|
TOPABSTRACTINTRODUCTIONRESULTSDISCUSSIONMATERIALS AND METHODSREFERENCES |
|---|
RNA Extraction
Total RNA was extracted from mouse tissues using Trizol (Invitrogen) and digested with DNase (Ambion, Inc., Austin, TX). cDNA was synthesized from 5 µg of total RNA using Superscript II (Invitrogen) following the manufacturer’s instructions. A no RT control was included for each reaction.
RT-PCR Analysis
Tissue expression of mGLUT9a and mGLUT9b was studied by RT-PCR analysis. Primers were designed using the Primer Select program in DNASTAR to differentially recognize the mGLUT9 splice variants. To identify mGLUT9a, the following primers were used: forward, 5'-GGGTCACCAGCAGAGGAG, and reverse, 5'-TGGACCAAGGCAGGGACAA, which generated a band of 609 bp. The mGLUT9b-specific PCR was performed with the following primers: forward, 5'-TGAAAAGAACTCCGCAGAAACCAA; and reverse, 5'-CAGAAGCTCCAGCACAGACACCAG, which generated a band of 811 bp. One twentieth of the cDNA reaction was used as template for PCR. Hot start Taq DNA polymerase (Invitrogen) was used, and the reaction was amplified utilizing the PTC-100 thermal cycler (MJ Research, Inc., Watertown, MA). PCR cycle conditions were: 94 C for 1 min, and 35 cycles of 94 C for 30 sec, 57 C (for mGLUT9a) and 60 C (for mGLUT9b) for 30 sec, and 72 C for 55 sec. PCR amplicons were separated in a 1.5% agarose gel. These fragments were sequenced to verify their identity. Quality and initial amounts of cDNA template in each reaction were assessed by a control PCR with primers for mouse glyceraldehyde-3-phosphate dehydrogenase (GAPDH gene; forward, 5-TTGACCTCAACTACATGG-3'; and reverse, 5'-ATGAGGTCCACCACCCTG-3').
Real-Time Quantitative PCR
Total RNA was extracted using the RNeasy RNA isolation kit (QIAGEN, Chatsworth, CA). RNA was reverse transcribed according to the Superscript II (Invitrogen) protocol. Quantitative PCR assays were performed using Applied Biosystems 7000 Sequence Detection system. Taqman gene expression assays (Applied Biosystems) Mm01211146_m1 and Mm00455117_m1 were used to examine expression of mGLUT9a and mGLUT9b, respectively, according to the manufacturer’s instructions. Wells contained 10 µl Taqman Universal PCR master mix, 1 µl Taqman assay, and 100 ng cDNA in 9 µl. Assays were performed in triplicate. Diabetic and nondiabetic skeletal muscle was used as a negative control. The comparative threshold cycle (CT) method was used to quantify the relative levels of gene expression and was normalized to 18S ribosomal RNA levels (27). All data were expressed as change in threshold cycle between control and diabetic tissues normalized to skeletal muscle.
Tissue Extraction
Mouse heart, skeletal muscle, brain, lung, liver, and kidney were collected from normal 3-wk-old female (B6SJLF1/J) mice. Animals were killed and tissue was extracted and immediately frozen in liquid nitrogen. Tissues were also collected from diabetic mice 10 d after ip injection of streptozotocin (190 mg/kg). Blood glucose levels of animals were measured and were above 400 mg/dl. All animal protocols were compliant with the animal care committee at Washington University School of Medicine and in accordance with National Institutes of Health guidelines (Institutional Animal Care and Use Committee approval).
Functional Expression in Oocytes
Adult female X. laevis were obtained from Nasco and housed at 18 C on the 12-h light, 12-h dark cycle. Stage V/VI eggs were harvested from anesthetized frogs and placed in Modified Barth’s Media (MBM) isolation media [88 mM NaCl, 1 mM KCl, 0.33 mM Ca(NO3)2, 0.41 mM CaCl2, 0.82 mM MgSO4, 2.4 mM NaHCO3, 2.5 mM Na pyruvate, 0.1 mg/ml Penicillin, 0.05 mg/ml gentamycin sulfate, 10 mM HEPES at pH 7.5]. The follicular layer was removed by treatment for 2 h with type I collagenase (Sigma Chemical Co., St. Louis, MO) 0.02 g/ml. After selection, hypertonic phosphate treatment was applied to all the oocytes subjected to microinjection. Before mRNA microinjection the oocytes were incubated in MBM at 16–18 C for 24 h to restore their osmolarity. The oocytes were injected with 10–50 nl (
30 ng) synthetic mGLUT9b mRNA transcript and incubated for 4–6 d at 16–18 C.
Radiotracer Flux Assays
The influx experiments were performed at 20 C using pools of 10–12 oocytes for each condition with 14C-labeled hexose at a specific activity of 1 µCi/ml. Oocyte pools were washed with ice-cold MBM to stop the incubation, after which individual eggs were placed in vials and dissolved in 0.5ml 5% SDS for 30 min. Finally, scintillation fluid (5 ml) was added to each vial and radioactivity measured using a Beckman liquid scintillation counter LS6500 (Beckman Coulter, Inc., Fullerton, CA). All experiments were performed in triplicate, and the results were compared with the influx values obtained with water-injected oocytes.
Protein Isolation and Subcellular Fractionation
Protein from pooled tissue samples was extracted into ice-cold 10 mM HEPES buffer supplemented with 250 mM sucrose, 1 mM EDTA, and protease inhibitor mix (PI mix: 10 µl aprotinin, 10 µg leupeptin, 10 µg antipain, 10 µg benzamidine, 50 µg trypsin inhibitor, 10 µg chymostatin, 10 µg pepstatin A, and 0.87 mg phenylmethylsulfonylfluoride/ ml of buffer (Sigma). Tissues were homogenized on ice using a Potter Elvehjem homogenizer (Kimblenotes, Vineyard, NJ). The tissue homogenate was spun down at 1500 x g for 10 min at 4 C to separate the tissue debris. The supernatant was centrifuged at 200,000 x g for 45 min at 4 C to isolate the TM fraction. The TM pellet was resuspended in HEPES buffer with PI mix and stored at –20 C until analysis.
To further define the localization of mGLUT9, subcellular fractionation was performed to separate PM, high-density microsome (HDM), and low-density microsome fractions (LDM). Briefly, the homogenate was spun down at 14,000 x g for 15min. The pellet was resuspended in HEPES buffer with PI mix and overlaid on an equal volume of 38% sucrose and spun at 100,000 x g for 1 h in a swinging bucket rotor. The PM fraction was isolated at the interface as a white puffy band and pelleted at 50,000 x g for 30 min. The supernatant from the first spin was centrifuged at 50,000 x g for 30 min to obtain the HDM fraction. Finally, the resultant supernatant was recentrifuged at 200,000 x g for 75 min to isolate the LDM fraction. PM, HDM, and LDM fractions were homogenized in HEPES buffer with PI mix and stored frozen until analysis. Protein was quantified using the BCA reagent (Pierce Chemical Co., Rockford, IL). Purity of the subcellular fractions was tested using antibodies to Na/K-ATPase protein (a generous gift from Dr. Robert Mercer, Washington University School of Medicine, St. Louis, MO), GM130, a Golgi matrix protein (Pharmingen, San Diego, CA), and Calnexin, an integral endoplasmic reticulum membrane protein (Stressgen, Victoria, British Columbia, Canada).
Antibodies and Markers
Protein expression was analyzed using mGLUT9-specific antisera generated in sheep against a C-terminal 20-amino acid peptide (SQTEPDSSSTLDSYGQNKIV) (1). Immune sera purified using a HiTrap protein G column (Amersham Biosciences, Piscataway, NJ) was used for Western blots and fluorescent staining. Protein G purified preimmune sera was used as the negative control. Horseradish peroxidase-conjugated preabsorbed goat antisheep secondary antibody and mouse antiactin antibody were from Chemicon Inc. (Temecula, CA). Alexa fluor 488 and 568 conjugated secondary antibodies and TO-PRO-3 iodide nuclear marker were obtained from Molecular Probes (Eugene, OR). The GLUT2 antibody was a generous gift from Dr. B. Thorens (University of Lausanne, Lausanne, Switzerland). L. tetragonolobus (Vector Laboratories, Inc., Burlingame CA), D. biflorus (Vector Laboratories), and Tamm-Horsfall polyclonal antibody (Biomedical Technologies, Stoughton, MA; and gift of Dr. Jeffrey Minor, Washington University School of Medicine) were used to stain different parts of the mouse nephron.
Western Blot Analysis
TM fraction (30 µg) from liver and kidney were separated by 10% SDS-PAGE and transferred to nitrocellulose using the miniprotein system (Bio-Rad Laboratories, Hercules, CA). TM fractions isolated from MDCK cells overexpressing mGLUT9 were used as a positive control for Western blots (for overexpression methods, see below). Blots were blocked with 5% milk for 1 h and probed with sheep anti-mGLUT9 (1:1000) overnight at 4 C. Horseradish peroxidase-conjugated goat antisheep antibody (1:20,000) was used as the secondary antibody. Signal was detected by West Dura chemiluminescence detection system (Pierce Chemical Co.). To further characterize mGLUT9, 10 µg from PM fractions of each tissue was digested with PNGase F according to the manufacturer’s instructions (New England Biolabs, Beverly, MA). To resolve the GLUT9 splice variants, which differ in size by about 4 kDa, deglycosylated tissue samples were prepared and run on a standard (20 x 20 cm) 10% SDS-PAGE. PM fractions from MDCK cells overexpressing mGLUT9a and mGLUT9b were mixed at equal amounts and digested to serve as the positive control.
Tissue Staining for Endogenous mGLUT9 Expression and Colocalization Studies
Bouin’s fixed paraffin-embedded liver and kidney tissues were used for the immunohistological staining procedure using the Vector staining kit specific for sheep primary antibody (Vector Laboratories). Sections were precooked with citrate buffer (pH 5.2) and blocked with rabbit serum. Sections were incubated with mGLUT9 antibody (10 µg/ml) overnight at 4 C and secondary antibody for 1 h at room temperature. 3,3'-DAB substrate was used to identify the mGLUT9 and counter stained with hematoxylin. Negative controls were stained with preimmune sera (10 µg/ml).
Frozen tissues mounted in Optimal Cutting Temperature (O.C.T.) compound (Electron Microscopy Sciences, Washington PA), were sectioned using a cryostat and used for immunofluorescence staining. Sections were fixed with 3% paraformaldehyde and stained with anti-mGLUT9 (10 µg/ ml), anti-mGLUT2 (15 µg/ml), L. tetragonolobus (1:200), D. biflorus (1:1000), or Tamm-Horsfall antibody (1:400). Sections stained with preimmune sera or normal species-specific sera were used as the negative control. Secondary antibody specific for appropriate host species conjugated with Alexa fluoro 488 and TO-PRO-3-iodide nuclear staining was used for the fluorescence staining. Dual staining was performed sequentially incubating with appropriate secondary antibodies. Fluorescence images were obtained using a confocal microscope operated with Nikon EZ7.1 software (Nikon ECLIPSE E800; Nikon Instruments Corp., Melville, NY). Dual fluorescence signal collected by sequential exposure to each laser using the channel series control reduced bleeding between channels.
Cell Lines and in Vitro Expression Studies
MDCK cells were grown in DMEM supplemented with 10% fetal calf serum, 1% Penicillin /Streptomycin 2% L-glutamine, and 1% sodium pyruvate (Fisher Scientific, Hanover Park, IL). Cells were transfected when they were 50–70% confluent using Fugene 6 reagent (Roche, Indianapolis, IN) according to the manufacturer’s instructions. After 48 h, transfection media supplemented with G418 (0.8 µg/ml) was added to select the transfected cells. A bulk stable population was used for protein extraction. Subcellular fractionation was performed as described above (10 µg). Protein was subjected to SDS-PAGE and Western blot assays. PNGase F digestion was also conducted as explained for the tissues.
Next, to investigate the presence of a putative N-glycosylation site in the first exofacial loop of mGLUT9, the sequence, 71NGT was mutated to 71QGT using the QuikChange Site-Directed Mutagenesis kit (Stratagene, La Jolla, CA). Mutated protein expression was analyzed by overexpressing these constructs in MDCK cells.
Immunocytochemical Studies
Transfected cells were grown for 48 h and selected for stable expression using G418. Monoclonal cell lines were generated by serial dilution. Three monoclonal MDCK cell lines expressing mGLUT9a and mGLUT9b were grown on polyethylene terephthalate (PET) membranes (0.4-µm pore size, from BD Biosciences, Franklin Lakes, NJ). Monolayer cultures were polarized for 5 d. Cells were fixed in 3% paraformaldehyde for 15 min and permeablized with 0.1% Triton X100 for 5 min and blocked with 2% BSA for 30 min. mGLUT9 antibody (10 µg/ml) staining was conducted overnight at 4 C. For fluorescence detection, antisheep secondary antibody conjugated with Alexa fluoro 488 and nuclear staining with TO-PRO-3 iodide dye were used. mGLUT9 expression in polarized MDCK cells was observed by confocal microscopy to analyze the vertical distribution.
Comparison of Normal and Diabetic Tissues
mGLUT9 expression was compared in diabetic vs. control using 30 µg of TM fractions for both liver and kidney. Experiments were performed in triplicate. For quantitative analysis, respective blots were stripped and reprobed with an actin antibody (1:5000). mGLUT9 expression was normalized to actin. Real-time PCR was used to quantify the relative levels of gene expression in diabetic tissue as compared with control. The comparative threshold cycle (Ct) was measured and then normalized to 18S rRNA levels. All data was expressed as difference in the change in threshold cycle (Ct) between control and diabetic tissues normalized to skeletal muscle. Diabetic and nondiabetic skeletal muscle was used as a negative control. Both isoforms were expressed at relatively low levels in skeletal muscle, and no increase was seen in the diabetic tissue. All real-time experimental values are expressed as change in cycle threshold compared with skeletal muscle. All values are expressed as means ± SEM.
Statistical Analysis
Protein expression was quantitated using densitometry, utilizing National Institutes of Health (NIH) Image software (Bethesda, MD). mGLUT9 expression was normalized to the corresponding actin band. Data were expressed as a percent normalized to control ± SEM. Statistical significance of the means was calculated in triplicate groups, and P < 0.05 was considered significant. Student’s t test was used for statistical analysis of diabetic vs. control tissue. ANOVA with Fisher’s post hoc test was used for the comparison of diabetic vs. control mRNA levels by real-time PCR.
|
ACKNOWLEDGMENTS |
|---|
|
FOOTNOTES |
|---|
Abbreviations: DAB, 3,3'-Diaminobenzidine; GLUT, glucose transporter; HDM, high-density membrane; LDM, low-density membrane; MBM, modified Barth’s media; MDCK cell, Madin Darby canine kidney cell; PI mix, protease inhibitor mix; PM, plasma membrane; PNGase F, peptide-N-glycosidase F; TM, total membrane.
This work was supported by National Institutes of Health (NIH) Training Grant 5-T32-DK07296-22 (to C.K.) and NIH Grant R21DK59518 and an American Diabetes Association research grant (to K.H.M.)
Received for publication January 6, 2005. Accepted for publication November 10, 2005.
|
REFERENCES |
|---|
|
TOPABSTRACTINTRODUCTIONRESULTSDISCUSSIONMATERIALS AND METHODSREFERENCES |
|---|
C(T)) method. Methods 25:402–408[CrossRef][Medline]This article has been cited by other articles:
 |
|
 |
|
  S. A. Evans, M. Doblado, M. M. Chi, J. A. Corbett, and K. H. Moley Facilitative Glucose Transporter 9 Expression Affects Glucose Sensing in Pancreatic {beta}-Cells Endocrinology, December 1, 2009; 150(12): 5302 - 5310. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Doblado and K. H. Moley Facilitative glucose transporter 9, a unique hexose and urate transporter Am J Physiol Endocrinol Metab, October 1, 2009; 297(4): E831 - E835. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Preitner, O. Bonny, A. Laverriere, S. Rotman, D. Firsov, A. Da Costa, S. Metref, and B. Thorens Glut9 is a major regulator of urate homeostasis and its genetic inactivation induces hyperuricosuria and urate nephropathy PNAS, September 8, 2009; 106(36): 15501 - 15506. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Bibert, S. K. Hess, D. Firsov, B. Thorens, K. Geering, J.-D. Horisberger, and O. Bonny Mouse GLUT9: evidences for a urate uniporter Am J Physiol Renal Physiol, September 1, 2009; 297(3): F612 - F619. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. T. Kim and K. H. Moley Regulation of Facilitative Glucose Transporters and AKT/MAPK/PRKAA Signaling via Estradiol and Progesterone in the Mouse Uterine Epithelium Biol Reprod, July 1, 2009; 81(1): 188 - 198. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Frolova, L. Flessner, M. Chi, S. T. Kim, N. Foyouzi-Yousefi, and K. H. Moley Facilitative Glucose Transporter Type 1 Is Differentially Regulated by Progesterone and Estrogen in Murine and Human Endometrial Stromal Cells Endocrinology, March 1, 2009; 150(3): 1512 - 1520. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Ding and I. J. Kullo Genome-wide Association Studies for Atherosclerotic Vascular Disease and Its Risk Factors. Circ Cardiovasc Genet, February 1, 2009; 2: 63 - 72. [Full Text] [PDF]
|
|
|
|
 |
|
 S. T. Kim and K. H Moley Paternal effect on embryo quality in diabetic mice is related to poor sperm quality and associated with decreased glucose transporter expression Reproduction, September 1, 2008; 136(3): 313 - 322. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Wilson-O'Brien, C. L. DeHaan, and S. Rogers Mitogen-Stimulated and Rapamycin-Sensitive Glucose Transporter 12 Targeting and Functional Glucose Transport in Renal Epithelial Cells Endocrinology, March 1, 2008; 149(3): 917 - 924. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Sung Tae Kim and K. H. Moley The Expression of GLUT8, GLUT9a, and GLUT9b in the Mouse Testis and Sperm Reproductive Sciences, July 1, 2007; 14(5): 445 - 455. [Abstract] [PDF]
|
|
|
|
|
|
B. D. Schaan, U. F. Machado, S. Rogers, and D. J. Kelly Glucose transporters in animal models of diabetes and hypertension Am J Physiol Renal Physiol, September 1, 2006; 291(3): F702 - F703. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
